Soft tissue sarcomas

Kelly K. Hunt, Shreyaskumar R. Patel, Alan Pollack

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The designation soft tissue sarcoma encompasses a wide diversity of more than 50 histiotypes of which about 6600 cases are diagnosed annually in this country. Tumor grade, size, depth, histological characteristics, and site of origin are important prognostic factors that influence the overall outcome in patients with soft tissue sarcoma. Patients with small (5 cm, T1) primary tumors who have no evidence of distant metastatic disease are managed by local therapy consisting of surgery alone or in combination with radiation therapy. The use of systemic therapy is generally limited to patients with metastatic disease, those with small cell sarcomas of any size, or those patients with large (5 cm, T2) high-grade or 10 cm intermediate-grade tumors who are at high risk of developing metastatic disease. The primary objective of multimodality treatment is to render patients free of disease. In patients for whom this endpoint is attainable, the therapeutic intent is cure; in patients for whom this is not accomplished, the intent is palliation of existing or potential symptoms.

Original languageEnglish (US)
Title of host publicationIntegrated Cancer Management
Subtitle of host publicationSurgery, Medical Oncology, and Radiation Oncology
PublisherCRC Press
Pages394-415
Number of pages22
ISBN (Electronic)9780824746780
ISBN (Print)9780824771959
StatePublished - Jan 1 1999
Externally publishedYes

Fingerprint

Sarcoma
Small Cell Sarcoma
Neoplasms
Therapeutics
Radiotherapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hunt, K. K., Patel, S. R., & Pollack, A. (1999). Soft tissue sarcomas. In Integrated Cancer Management: Surgery, Medical Oncology, and Radiation Oncology (pp. 394-415). CRC Press.

Soft tissue sarcomas. / Hunt, Kelly K.; Patel, Shreyaskumar R.; Pollack, Alan.

Integrated Cancer Management: Surgery, Medical Oncology, and Radiation Oncology. CRC Press, 1999. p. 394-415.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hunt, KK, Patel, SR & Pollack, A 1999, Soft tissue sarcomas. in Integrated Cancer Management: Surgery, Medical Oncology, and Radiation Oncology. CRC Press, pp. 394-415.
Hunt KK, Patel SR, Pollack A. Soft tissue sarcomas. In Integrated Cancer Management: Surgery, Medical Oncology, and Radiation Oncology. CRC Press. 1999. p. 394-415
Hunt, Kelly K. ; Patel, Shreyaskumar R. ; Pollack, Alan. / Soft tissue sarcomas. Integrated Cancer Management: Surgery, Medical Oncology, and Radiation Oncology. CRC Press, 1999. pp. 394-415
@inbook{00ccda15563249f9b0f68c3ea5aee06b,
title = "Soft tissue sarcomas",
abstract = "The designation soft tissue sarcoma encompasses a wide diversity of more than 50 histiotypes of which about 6600 cases are diagnosed annually in this country. Tumor grade, size, depth, histological characteristics, and site of origin are important prognostic factors that influence the overall outcome in patients with soft tissue sarcoma. Patients with small (5 cm, T1) primary tumors who have no evidence of distant metastatic disease are managed by local therapy consisting of surgery alone or in combination with radiation therapy. The use of systemic therapy is generally limited to patients with metastatic disease, those with small cell sarcomas of any size, or those patients with large (5 cm, T2) high-grade or 10 cm intermediate-grade tumors who are at high risk of developing metastatic disease. The primary objective of multimodality treatment is to render patients free of disease. In patients for whom this endpoint is attainable, the therapeutic intent is cure; in patients for whom this is not accomplished, the intent is palliation of existing or potential symptoms.",
author = "Hunt, {Kelly K.} and Patel, {Shreyaskumar R.} and Alan Pollack",
year = "1999",
month = "1",
day = "1",
language = "English (US)",
isbn = "9780824771959",
pages = "394--415",
booktitle = "Integrated Cancer Management",
publisher = "CRC Press",

}

TY - CHAP

T1 - Soft tissue sarcomas

AU - Hunt, Kelly K.

AU - Patel, Shreyaskumar R.

AU - Pollack, Alan

PY - 1999/1/1

Y1 - 1999/1/1

N2 - The designation soft tissue sarcoma encompasses a wide diversity of more than 50 histiotypes of which about 6600 cases are diagnosed annually in this country. Tumor grade, size, depth, histological characteristics, and site of origin are important prognostic factors that influence the overall outcome in patients with soft tissue sarcoma. Patients with small (5 cm, T1) primary tumors who have no evidence of distant metastatic disease are managed by local therapy consisting of surgery alone or in combination with radiation therapy. The use of systemic therapy is generally limited to patients with metastatic disease, those with small cell sarcomas of any size, or those patients with large (5 cm, T2) high-grade or 10 cm intermediate-grade tumors who are at high risk of developing metastatic disease. The primary objective of multimodality treatment is to render patients free of disease. In patients for whom this endpoint is attainable, the therapeutic intent is cure; in patients for whom this is not accomplished, the intent is palliation of existing or potential symptoms.

AB - The designation soft tissue sarcoma encompasses a wide diversity of more than 50 histiotypes of which about 6600 cases are diagnosed annually in this country. Tumor grade, size, depth, histological characteristics, and site of origin are important prognostic factors that influence the overall outcome in patients with soft tissue sarcoma. Patients with small (5 cm, T1) primary tumors who have no evidence of distant metastatic disease are managed by local therapy consisting of surgery alone or in combination with radiation therapy. The use of systemic therapy is generally limited to patients with metastatic disease, those with small cell sarcomas of any size, or those patients with large (5 cm, T2) high-grade or 10 cm intermediate-grade tumors who are at high risk of developing metastatic disease. The primary objective of multimodality treatment is to render patients free of disease. In patients for whom this endpoint is attainable, the therapeutic intent is cure; in patients for whom this is not accomplished, the intent is palliation of existing or potential symptoms.

UR - http://www.scopus.com/inward/record.url?scp=85056974149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056974149&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85056974149

SN - 9780824771959

SP - 394

EP - 415

BT - Integrated Cancer Management

PB - CRC Press

ER -